Arimoclomol Completed Phase 2 / 3 Trials for Inclusion Body Myositis (IBM) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2 / 3
clinicaltrials.gov IdentifierTitleDrugs
NCT02753530Study of Arimoclomol in Inclusion Body Myositis (IBM)